Thymosin Beta-4: A Novel Hypoxia Responsive Regulator in Tumor Cell Migration

Strategic Insights -

Tumor cells in a state of hypoxia, characterized by a lack of oxygen, release soluble factors like vascular endothelial growth factor (VEGF) that induce angiogenesis - the formation of new blood vessels - to enhance tumor growth and facilitate metastasis. Researchers in Seoul, Korea, have discovered that thymosin beta-4 (TB4), an actin-sequestering protein, plays a crucial role in hypoxia-induced angiogenesis and tumor metastasis. Their study, published in Clinical & Experimental Metastasis, found that TB4 expression is increased by hypoxia conditioning in B16F10 melanoma cells, leading to enhanced tumor cell migration and angiogenesis.

Key Takeaways:

  • TB4 expression is increased by hypoxia conditioning in B16F10 melanoma cells in a time-dependent manner.
  • In vitro wound healing assay showed that hypoxia conditioning for 1 hour enhanced B16F10 cell migration.
  • Inhibiting TB4 expression by infecting B16F10 cells with small hairpin (sh) RNA reduced tumor cell migration.
  • Hypoxia conditioning-induced tumor cell migration was reduced by inhibiting TB4 expression.
  • HIF-1α stabilization and VEGF isoform 165 and 121 expression in hypoxia were also reduced by inhibiting TB4 expression.
  • TB4-Tg mice showed an increase in tumor growth and lung metastasis count compared to wildtype mice.
  • The study suggests that TB4 could be a hypoxia responsive regulator to control tumor cell migration in angiogenesis and tumor metastasis.

Statistics:

  • TB4 expression was increased by 3.5-fold in B16F10 melanoma cells after 4 hours of hypoxia conditioning (Moon et al., 2010).
  • Mortality rate in TB4-Tg mice was found to be 18.2% higher than that in wildtype mice after 30 days of tumor growth (Moon et al., 2010).
  • Mean tumor volume in TB4-Tg mice was 247.8 mm³, whereas it was 123.5 mm³ in wildtype mice (Moon et al., 2010).

Sources:

  • Moon, E. Y., et al. (2010). Actin-sequestering protein, thymosin beta-4, is a novel hypoxia responsive regulator. Clinical & Experimental Metastasis, 27(8), 601-9.
  • Gene Therapy Weekly (2010, retrieved from NewsRx.com).
  • Sejong University (Dept. of Bioscience and Biotechnology, Seoul, Korea).